Related Experiment Video
Updated: Mar 5, 2026
07:15
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
Published on: July 28, 2020
10.4K
Staged reconstruction brachytherapy has lower overall cost in recurrent soft-tissue sarcoma
Arash O Naghavi1, Ricardo J Gonzalez2, Jacob G Scott3
1Radiation Oncology; Both authors contributed equally to this work.
Journal of Contemporary Brachytherapy
|March 28, 2017
Summary
Staged reconstruction (SR) offers better local control and is more cost-effective for recurrent soft tissue sarcoma (STS) than immediate reconstruction (IR). SR leads to lower overall costs due to reduced local failures, aligning with value-based care principles.
Area of Science:
- Oncology
- Surgical Oncology
- Health Economics
Background:
- Adjuvant brachytherapy (AB) for recurrent soft tissue sarcoma (STS) involves immediate reconstruction (IR) and staged reconstruction (SR).
- While SR may improve local control and reduce toxicity, its cost-effectiveness compared to IR remains unclear.
- Value-based care necessitates understanding the economic implications of different treatment modalities.
Purpose of the Study:
- To compare the cost-effectiveness of staged reconstruction (SR) versus immediate reconstruction (IR) in patients with recurrent extremity soft tissue sarcoma (STS) undergoing adjuvant brachytherapy.
- To identify which reconstruction technique offers better value in the context of recurrent STS treatment.
Main Methods:
- A retrospective review of 22 patients with recurrent extremity STS treated with resection and AB.
- Hospital charges were analyzed to compare costs between SR and IR at initial treatment, 6-month intervals, and cumulatively at 18 months.
- Multivariate analysis assessed factors influencing treatment costs, including hospital stay and local failure.
Main Results:
- Staged reconstruction (SR) demonstrated superior 18-month local control (85% vs. 42%, p=0.034) compared to immediate reconstruction (IR).
- Although SR involved a longer initial hospital stay (10 vs. 3 days, p=0.002), total hospital stay at 18 months was similar.
- At 18 months, SR was associated with significantly lower cumulative costs (~$175K less, p=0.005), primarily due to reduced costs from local failures.
Conclusions:
- Staged reconstruction (SR) is more cost-effective than immediate reconstruction (IR) for recurrent soft tissue sarcoma (STS).
- Lower rates of local failure with SR translate to significant cost savings, supporting its consideration in value-based healthcare.
- SR should be considered a preferred approach for recurrent STS, balancing oncologic outcomes and economic value.
